| Indication | HPV-related cancers and pre-cancerous lesions |
| Drug | GARDASIL 9 |
| Mechanism of Action | HPV vaccine |
| Company | Merck |
| Category | Regulatory Milestone |
| Sub Category | Approval Granted |
| Therapeutic Area | Infectious Diseases & Vaccines |
| Approved Market/Region | U.S. |
| Approval Date | December 11, 2014 |
| Patient Population (Age) | Girls and young women 9 to 26 years of age, boys 9 to 15 years of age |
| HPV Types Covered | 6, 11, 16, 18, 31, 33, 45, 52, 58 |
| Comparator Drug | GARDASIL |
| Primary Efficacy Endpoint | Combined incidence of cervical, vaginal, and vulvar cancers, CIN 2/3, AIS, VIN 2/3, and VaIN 2/3 caused by HPV types 31, 33, 45, 52, 58 |
| Efficacy (Primary Endpoint) | 96.7% (95% CI; 80.9, 99.8) |
| Number of Participants (Study 1) | 14,204 women |
| Follow-up Duration (Study 1) | Median 40 months |
| Dosage Schedule | 0, 2 months, 6 months |
FDA Approves Merck's GARDASIL 9 for Broad HPV Cancer Prevention
Merck announced that the U.S. Food and Drug Administration (FDA) approved GARDASIL 9, its 9-valent human papillomavirus (HPV) vaccine, on December 11, 2014. The vaccine is approved for girls and young women aged 9 to 26, and boys aged 9 to 15, to prevent cervical, vulvar, vaginal, and anal cancers, pre-cancerous lesions, and genital warts caused by nine specific HPV types (6, 11, 16, 18, 31, 33, 45, 52, 58). This approval offers the potential to prevent approximately 90% of cervical cancers caused by HPV, expanding protection beyond the quadrivalent GARDASIL vaccine. Clinical studies demonstrated high efficacy, including 96.7% efficacy against combined incidence of cervical, vaginal, and vulvar cancers and high-grade disease caused by the five additional HPV types.
- GARDASIL 9 significantly broadens protection against HPV-related diseases by including five additional high-risk HPV types (31, 33, 45, 52, 58) beyond those in the original GARDASIL vaccine. This expansion is crucial for public health, as these nine types collectively cause about 90% of cervical cancer cases and a high percentage of other HPV-related cancers and genital warts. The U.S. Centers for Disease Control and Prevention (CDC) has prioritized increasing HPV vaccination rates, noting that improved coverage could prevent tens of thousands of cervical cancer cases.
- The efficacy of GARDASIL 9 was rigorously evaluated in a large, active comparator-controlled, double-blind, randomized clinical trial (Study 1) involving over 14,200 women. In the per-protocol efficacy population, GARDASIL 9 achieved 96.7% efficacy (95% CI; 80.9, 99.8) against the combined incidence of cervical, vaginal, and vulvar cancers and high-grade lesions (CIN 2/3, AIS, VIN 2/3, VaIN 2/3) caused by the five additional HPV types (31, 33, 45, 52, 58).
- Immunogenicity studies confirmed the vaccine's effectiveness in adolescents aged 9 to 15, inferring protection against vaccine HPV types based on non-inferior antibody responses compared to 16- through 26-year-old women. These studies also showed non-inferiority for HPV types 6, 11, 16, and 18 compared to GARDASIL. Across all trials, at least 99.5% of individuals developed seropositivity for each of the nine vaccine HPV types by Month 7, supporting broad and consistent immune response.
The Unmet Need for Broader HPV Cancer Prevention
Recent literature highlights persistent gaps in HPV vaccination coverage, screening participation, and therapeutic options for established HPV-driven disease. Efforts over the past 3 years have focused on under-vaccinated cohorts, under- or never-screened populations, and development of non-conventional therapies to address HPV persistence and immune evasion.
Men who have sex with men with elevated anal HPV risk: Among 497 MSM in San Francisco in 2023, 44.9% reported HPV vaccination, with lower uptake in older age groups and those without recent healthcare contact; among HIV-negative MSM in Urumqi, Xinjiang between April 2016 and June 2023, prevalence rates of high-risk HPV and low-risk HPV were 37.99% and 25.97%, with receptive anal intercourse associated with incident and persistent infection.
Adolescent girls and catch-up cohorts with suboptimal vaccine coverage: Globally, coverage with the first dose in 9-14-year-old girls was estimated at 56.9% in 2024 across 147 countries; in China parental willingness increased to 56.6% in 2023 yet vaccination rate among teenage girls was 9.8%, in Japan 39.0% of female university students born between April 2, 1997, and April 1, 2006 were vaccinated, and in Lesotho HPV dose 1 coverage was 85% while dose 2 coverage was 52.9%, reflecting a 32% dropout rate with lower completion in out-of-school girls.
Under- or never-screened and underserved women facing screening barriers: In Hong Kong 43.7% of participants were never or under-screened with overall self-sampling uptake rate of 68.9%; in Victoria, Australia 29% of 598,055 cervical screening tests from 1 July 2022 to 30 June 2024 were self-collected with increased uptake in older age groups, regional areas, and under- and never-screened women; in Singapore screening rates were at 43%, well below the national target of 70%, with embarrassment, privacy concerns and discomfort cited as barriers.
Populations affected by disrupted programs and fragmented systems: In low- and middle-income countries HPV vaccination coverage declined substantially during the COVID-19 pandemic, with reductions of up to 90% reported; in Canada national HPV vaccine uptake remains suboptimal at about 64%, far below the 90% coverage target by 2025; in Australia 49% of pregnant women booked for public antenatal care were overdue/never-screened.
Patients with established infection or HPV-driven malignancies lacking targeted therapies: Conventional modalities such as chemotherapy, radiotherapy, and surgery are associated with nonspecific toxicity, diminished quality of life, treatment resistance, and elevated recurrence rates and are not specifically designed to target persistent HPV infection; emerging approaches include nanocarrier-based platforms, siRNA-mediated E6/E7 silencing and CRISPR-based disruption of the HPV genome, therapeutic vaccines, immune checkpoint inhibition, and γδ T-cell-based immunotherapy.
GARDASIL 9's Efficacy and Safety Profile Unveiled
Recent studies in HPV-related cancers have evaluated immune checkpoint inhibitor-based combinations for persistent, recurrent or metastatic cervical cancer. These trials enrolled previously treated or immunotherapy-naive patients and reported objective response, survival and safety outcomes.
Serplulimab plus nab-paclitaxel in previously treated PD-L1-positive advanced cervical cancer (ClinicalTrials.gov, identifier NCT04150575): patients received serplulimab 4.5 mg/kg for up to 2 years (35 dosing cycles) plus nab-paclitaxel 260 mg/m for up to six cycles once every 3 weeks. IRRC-assessed ORR was 57.1% (95% confidence interval [CI] 34.0-78.2%); 3 (14.3%) patients achieved complete response and 9 (42.9%) partial response, median DOR was not reached (NR) (95% CI 4.1-NR), median PFS was 5.7 months (95% CI 3.0-NR), and median OS was 15.5 months (95% CI 10.5-NR). Seventeen (81.0%) patients experienced grade ≥3 treatment-emergent adverse events, grade ≥3 adverse drug reactions were reported in 7 (33.3%) patients, and immune-related adverse events occurred in 12 (57.1%) patients.
VB10.16 combined with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer (NCT04405349, phase 2a study): patients received 3 mg VB10.16 (every 3 weeks (Q3W) for 12 weeks, hereafter every 6 weeks) combined with 1,200 mg atezolizumab (Q3W) for 48 weeks in total. ORR was 19.1% (95% CI 9.1% to 33.3%), median duration of response was not reached (n.r.) (95% CI 2.2 to n.r.), median progression-free survival was 4.1 months (95% CI 2.1 to 6.2), and median overall survival was 21.3 months (95% CI 8.5 to n.r.), with ORR of 29.2% (95% CI 12.6 to 51.1) in programmed death-ligand 1 (PD-L1)-positive patients (n=24). AEs related to VB10.16 were non-serious and mainly mild injection site reactions (9 of 52 patients), with no signs of new toxicities other than what was already described with atezolizumab.
Pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025, phase II study): patients received pembrolizumab (200 mg every three weeks) and olaparib (600 mg daily) until disease progression or unacceptable toxicity. The ORR was 3.8% (90% CI, 0.2%-17.0%), the disease control rate was 50.0%, and the median PFS was 3.4 months. All patients experienced AEs with grade ≥ 3 events in 60.7%, hematologic toxicities were the most common severe events, and 4 patients discontinued olaparib due to adverse events (AEs).
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826, phase III, double-blind): pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles plus platinum-based chemotherapy, with or without bevacizumab. In the PD-L1 CPS ≥1 (N = 548), all-comer (N = 617), and CPS ≥10 (N = 317) populations, median OS with pembrolizumab-chemotherapy versus placebo-chemotherapy was 28.6 months versus 16.5 months (hazard ratio [HR] for death, 0.60 [95% CI, 0.49 to 0.74]), 26.4 months versus 16.8 months (HR, 0.63 [95% CI, 0.52 to 0.77]), and 29.6 months versus 17.4 months (HR, 0.58 [95% CI, 0.44 to 0.78]), respectively. The incidence of grade ≥3 adverse events was 82.4% with pembrolizumab-chemotherapy and 75.4% with placebo-chemotherapy.
Advancing HPV Prevention: GARDASIL 9's Impact
For recurrent, metastatic and locally advanced cervical cancer, immune checkpoint inhibitors combined with chemotherapy or chemoradiotherapy and antibody-drug conjugates have reshaped standards. The phase III KEYNOTE-826 trial demonstrated that pembrolizumab combined with chemotherapy significantly improved overall survival in recurrent or metastatic cervical cancer, while the KEYNOTE-A18 trial showed that pembrolizumab in combination with CRT followed by maintenance therapy achieved a 36-month OS rate of 82.6% in locally advanced disease. The antibody-drug conjugate tisotumab vedotin significantly prolonged OS to 11.5 months in previously treated recurrent or metastatic cases in the phase III innovaTV 301 trial. A meta-analysis of 5 RCTs totaling 3302 patients showed addition of ICIs to CT or CRT significantly improved PFS (HR = 0.661, 95% CI: 0.599-0.731) and OS (HR = 0.664, 95% CI: 0.590-0.747), with PFS and OS benefits particularly pronounced in patients with PD-L1 combined positive score ≥ 1, but higher incidence of grade 3-5 AEs (RR = 1.076, 95% CI: 1.032-1.123). Additional phase II data include toripalimab plus platinum-based chemoradiotherapy with ORR and disease control rate both 87.8% and grade 3 or higher adverse events in 17 (20.7%) patients, serplulimab plus nab-paclitaxel with IRRC-assessed ORR of 57.1% (95% confidence interval [CI] 34.0-78.2%), median PFS of 5.7 months (95% CI 3.0-NR) and median OS of 15.5 months (95% CI 10.5-NR), camrelizumab plus apatinib with median OS of 20.3 months (95% CI, 9.3-36.9) and 24-month OS rate of 47.8% (95% CI, 31.7-62.3), sintilimab plus anlotinib with ORR of 54.8% (95% CI, 38.7 to 70.2) and median PFS of 9.4 months (95% CI, 8.0 to 14.6), and innovaTV 205 with confirmed ORR (median DOR) of 54.5% (8.6 months), 40.6% (not reached), 35.3% (18.2 months), and 65.8% (13.3 months), median PFS of 6.9, 5.3, 5.6, and 10.6 months and median OS of 25.5, 30.7, 15.3, and 28.0 months across arms D-F and H.
For HPV16-positive pre-cancerous lesions and HPV-driven solid tumors, therapeutic vaccines encoding E6 and E7 have shown preliminary clinical activity. In a Phase II trial in newly diagnosed HPV16-positive CIN3, three immunizations of Vvax001 (5 × 107 infectious particles) at a 3-week interval produced reduction in CIN3 lesion sizes in 17/18 (94%) patients, histopathologic complete response (regression to CIN grade 1 or no dysplasia) in 9/18 patients (50%) and HPV16 clearance in 10/16 patients (63%), with median and longest disease-free survival of 20 and 30 months and no serious adverse events. In a phase I dose-escalation trial of PepCan consisting of four peptides covering HPV type 16 E6 protein with Candida skin test reagent in women with biopsy-proven CIN2/3 (n = 24), best histological response was at the 50 μg dose level with regression rate of 83% (n = 6) and overall rate of 52% (n = 23), with vaccine-induced immune responses to E6 in 65% of recipients and systemic T-helper type 1 cells significantly increased after four vaccinations (P = 0.02). In recurrent HPV16+ cervical cancer after first-line chemotherapy, cemiplimab plus peltopepimut-S (NCT04646005) showed ORR (95% CI) of 16.8% (9.9-23.7), median DOR of 5.6 (3.5-not estimable) months, median OS and PFS of 13.3 (10.8-16.3) months and 3.0 (1.7-4.0) months, with treatment-emergent adverse events in 92.9% including injection-site reaction (38.9%) and anemia (25.7%). In recurrent/metastatic HPV16-positive head and neck cancer, peltopepimut-S plus cemiplimab versus cemiplimab alone did not meet its primary objective (ORR, 25.3% in peltopepimut-S arm vs 22.9% in placebo arm; p=0.735) with median OS of 26.9 vs 15.8 months and PFS of 20.3 vs 5.5 months, while patients with CPS ≥20 had higher ORR of 51.7% (95% CI, 32.5% to 70.6%) vs 25.8% (95% CI, 11.9% to 44.6%) and longer mOS of 34.8 vs 28.8 months.
For HPV-positive oropharyngeal squamous cell carcinoma, cisplatin-based concurrent chemoradiation remains the standard of care for locally advanced disease, with de-intensification under active evaluation. Replacing cisplatin with cetuximab results in inferior survival, and chemotherapy attenuation compromises outcomes without reducing toxicity. The TopROC prospective, two-arm, open label, multicenter, randomized comparative effectiveness study plans 280 patients randomly assigned (1:1) to transoral surgical resection with neck dissection followed by risk-adapted adjuvant therapy versus standard chemoradiation, with primary endpoint time to local or locoregional failure and 3 years of follow-up visits. Primary RT or CRT provides outstanding survival for early T-stage disease, with a consecutive series of 198 patients (82% male and 73% HPV-positive) showing grade 2 toxicity in 68%, grade 3 in 48% and grade 4 in 4%, gastrostomy tube dependence of 2.5% and 1% at 1 and 2 years, and improved 5-year overall survival in HPV-positive patients (86% vs 64%, p = 0.0026). Transoral surgery shows low 30-day mortality in an ACS-NSQIP cohort of 3,489 patients with 24 deaths (0.7% 30-day mortality rate), readmission of 8.9% and reoperation of 5.8%, and in US veterans (10,436 patients) up-front surgery was associated with csHR of stroke of 0.77 (95% CI, 0.66-0.91) versus definitive (chemo)radiotherapy with 10-year cumulative incidence of stroke of 12.5% (95% CI, 11.8%-13.3%). Response-stratified de-escalation using neoadjuvant chemotherapy followed by transoral robotic surgery, de-escalated (chemo)radiation to 50Gy, or standard chemoradiation to 70Gy showed rapid early ctHPV-DNA clearance after one cycle (≥95% reduction) predicted radiographic deep response (p=0.04) in 46 patients with 488 samples, median follow-up of 30 months and five recurrences (10.9%), with baseline ctHPV-DNA detected in 96% of evaluable patients.
A New Era for HPV Prevention: Expanding Cancer Protection
The FDA approval of the 9-valent human papillomavirus (HPV) vaccine, GARDASIL 9, marks a significant leap forward in the global fight against HPV-related cancers and diseases. This next-generation vaccine extends protection beyond the quadrivalent formulation by targeting five additional high-risk HPV types (31, 33, 45, 52, 58), which are collectively responsible for a substantial portion of cervical, vulvar, vaginal, and anal cancers, as well as precancerous lesions and genital warts. The literature consistently underscores HPV as a necessary cause of cervical cancer and a major contributor to other anogenital malignancies. With the potential to prevent approximately 90% of cervical cancers, this vaccine offers a more comprehensive primary prevention strategy, aligning with public health goals to drastically reduce the burden of these diseases.
The strategic implications are profound. This expanded coverage positions the 9-valent vaccine as the new standard of care, likely accelerating the shift away from older, less comprehensive vaccines. Its robust immunogenicity, particularly in younger adolescents, supports early vaccination programs, which are crucial for maximizing protective efficacy. Furthermore, emerging evidence supporting a 2-dose regimen for adolescents, and even potentially for young adults, offers a significant opportunity to simplify vaccination schedules. This simplification could enhance vaccine uptake and adherence, especially in resource-limited settings or where logistical challenges exist, as prolonged intervals between doses do not appear to diminish antibody responses.
However, the path to widespread impact is not without its challenges. Despite the vaccine's enhanced efficacy, persistent vaccine hesitancy and misinformation remain significant barriers to uptake across various populations. Studies indicate a growing percentage of individuals, including healthcare professionals, expressing doubts about vaccine safety and necessity. This is compounded by significant missed opportunities for vaccination in clinical settings, even among high-risk groups like childhood cancer survivors who are particularly vulnerable to HPV-related secondary cancers. Implementing the vaccine effectively also faces systemic hurdles, with providers citing educational gaps, complex guidelines, and workflow integration issues, particularly in specialized oncology settings. Moreover, the evolving global vaccine landscape, with new bivalent vaccines and ongoing research into single-dose regimens, suggests potential future competition and shifts in vaccination strategies that could influence the long-term market dynamics. Addressing these multifaceted challenges through targeted education, improved provider recommendations, and streamlined delivery mechanisms will be crucial to fully realize the public health potential of this advanced HPV vaccine.
Frequently Asked Questions
References
- [1] Hasegawa K, Ikeda Y et al.. Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2018 May. 29432282
- [2] Gu L, Zhu B et al.. Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer. The oncologist. 2026 Jun 6. 42332782
- [3] Hillemanns P, Zikan M et al.. Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study. Journal for immunotherapy of cancer. 2025 Jan 7. 39773564
- [4] Zhai C, Jin X et al.. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review. BMC geriatrics. 2024 Jan 8. 38191289
- [5] Wong S, Tang L et al.. Complications After Transoral Surgery for Oropharyngeal Cancer: An ACS-NSQIP Database Study. The Laryngoscope. 2025 Jul. 39835718
- [6] Xu Z, Wang M et al.. Promising outcomes of the PD-L1 inhibitor Socazolimab in recurrent and metastatic cervical cancer: a case report. Frontiers in oncology. 2025. 40206580
- [7] Westra TA, Stirbu-Wagner I et al.. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC infectious diseases. 2013 Feb 7. 23390964
- [8] Sakamoto M, Miyagi E et al.. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2019 Jul. 30879979
- [9] Harper DM. Current prophylactic HPV vaccines and gynecologic premalignancies. Current opinion in obstetrics & gynecology. 2009 Dec. 19923989
- [10] Costantino A, Haughey B et al.. Safety and Postoperative Outcomes of Transoral Surgery for Oropharyngeal Carcinoma in Older Adults. JAMA otolaryngology-- head & neck surgery. 2024 Oct 1. 39207743
- [11] Waltonen JD, Thomas SG et al.. Oropharyngeal Carcinoma Treated with Surgery Alone: Outcomes and Predictors of Failure. The Annals of otology, rhinology, and laryngology. 2022 Mar. 34056954
- [12] Wu X, Wang D et al.. Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study. Communications medicine. 2026 Apr 21. 42014919
- [13] Fujisaki M, Matsumoto K. [Latest Drug Therapies for Cervical Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2025 Dec. 41437601
- [14] Zafar M, Sweis N et al.. Advances and Challenges in the Treatment of HPV-Associated Lower Genital Tract Cancers by Immune Checkpoint Blockers: Insights from Basic and Clinical Science. Cancers. 2025 Apr 8. 40282436
- [15] Petar S, Marko S et al.. De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2021 Nov. 33599841
- [16] Jeong B, Krishnan G et al.. Oncological and functional outcomes of transoral surgery compared with non-surgical management in small-volume oropharyngeal cancer: a systematic review protocol. JBI evidence synthesis. 2023 Oct 1. 37246954
- [17] Riethmuller D. [Vaccination against human papillomavirus]. La Revue du praticien. 2010 Dec 20. 21425527
- [18] Lee A, Hawkes D et al.. Exponential uptake of HPV self-collected cervical screening testing 2 years since universal availability in Victoria, Australia. BMC medicine. 2025 Jul 1. 40598474
- [19] Greenfield WW, Stratton SL et al.. A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology. 2015 Oct. 26451301
- [20] Patra S, Shand H et al.. Beyond conventional therapies: immunotherapeutic strategies targeting HPV-associated cervical cancer. Immunotherapy. 2026 Apr-Apr. 42204874
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com














